Abstract-In angiotensin type 1 receptor-blocked rats, renal interstitial (RI) administration of des-aspartyl 1 -angiotensin II (Ang III) but not angiotensin II induces natriuresis via activation of angiotensin type 2 receptors. In the present study, renal function was documented during systemic angiotensin type 1 receptor blockade with candesartan in Sprague-Dawley rats receiving unilateral RI infusion of Ang III. Ang III increased urine sodium excretion, fractional sodium, and lithium excretion. RI coinfusion of specific angiotensin type 2 receptor antagonist PD-123319 abolished Ang III-induced natriuresis. The natriuretic response observed with RI Ang III was not reproducible with RI angiotensin (1-7) alone or together with angiotensin-converting enzyme inhibition. Similarly, neither RI angiotensin II alone or in the presence of aminopeptidase A inhibitor increased urine sodium excretion. In the absence of systemic angiotensin type 1 receptor blockade, Ang III alone did not increase urine sodium excretion, but natriuresis was enabled by the coinfusion of aminopeptidase N inhibitor and subsequently blocked by PD-123319. In angiotensin type 1 receptor-blocked rats, RI administration of aminopeptidase N inhibitor alone also induced natriuresis that was abolished by PD-123319. Ang III-induced natriuresis was accompanied by increased RI cGMP levels and was abolished by inhibition of soluble guanylyl cyclase. RI and renal tissue Ang III levels increased in response to Ang III infusion and were augmented by aminopeptidase N inhibition. These data demonstrate that endogenous intrarenal Ang III but not angiotensin II or angiotensin (1-7) induces natriuresis via activation of angiotensin type 2 receptors in the proximal tubule via a cGMP-dependent mechanism and suggest aminopeptidase N inhibition as a potential therapeutic target in hypertension. ) excretion (U Na V) and its effect on blood pressure are regulated by the intrarenal renin-angiotensin system. 1,2 Renin-angiotensin system actions are mediated largely by angiotensin II (Ang II) acting via 2 major receptors, angiotensin type 1 (AT 1 R) and angiotensin type 2 (AT 2 R). The activation of AT 1 Rs by Ang II induces vasoconstriction and increases renal tubule Na ϩ reabsorption, sympathetic nervous system activation, and secretion of aldosterone, vasopressin, and endothelin.
T he basal state of renal sodium (Na ϩ ) excretion (U Na V) and its effect on blood pressure are regulated by the intrarenal renin-angiotensin system. 1, 2 Renin-angiotensin system actions are mediated largely by angiotensin II (Ang II) acting via 2 major receptors, angiotensin type 1 (AT 1 R) and angiotensin type 2 (AT 2 R). The activation of AT 1 Rs by Ang II induces vasoconstriction and increases renal tubule Na ϩ reabsorption, sympathetic nervous system activation, and secretion of aldosterone, vasopressin, and endothelin. 1, 2 Collectively, these actions lead to the elevation of systemic blood pressure. Conversely, the activation of AT 2 Rs results in vasodilation and natriuresis. 3, 4 Angiotensin (1-7) (Ang [1] [2] [3] [4] [5] [6] [7] ) is another product of the reninangiotensin system for which its role in the kidney has not fully been established. In vitro studies in rat renal proximal tubule cells demonstrate that Ang(1-7) inhibits Na ϩ /K ϩ -ATPase activity, suggesting that Ang(1-7) might induce natriuresis in vivo possibly mediated via AT 2 Rs, the Ang(1-7) mas receptor, or both. 5 However, whether Ang(1-7) reduces tubular Na ϩ transport and induces natriuresis in vivo remains uncertain. 5 Ang II, the principal effector peptide of the renin-angiotensin system, is metabolized within the kidney to des-aspartyl 1 -Ang II (angiotensin III; Ang III) by aminopeptidase A (APA). 6 Intrarenal Ang III has been demonstrated recently to be a preferred AT 2 R agonist in the induction of natriuresis. [7] [8] [9] The natriuretic effect of exogenous renal interstitial (RI) Ang III infusion is markedly augmented by coinfusion with the selective aminopeptidase N (APN) inhibitor PC-18, which blocks the degradation of Ang III. 8 In contrast, RI Ang II infusion does not increase U Na V unless APN is concomitantly inhibited, and this natriuretic response is abolished when Ang II metabolism to Ang III is blocked with the APA inhibitor EC-33. 9 Previous studies have localized the precursors of angiotensin peptide synthesis, including angiotensinogen, renin, and angiotensin-converting enzyme (ACE) mRNA, to the renal proximal tubule. 1 Renal proximal tubule cells, which are responsible for reabsorption of Ϸ60% of filtered Na ϩ in the nephron, express a high level of AT 2 Rs, as verified by Western blot analysis and immunohistochemistry. 10, 11 A major cell signaling pathway of AT 2 Rs is the activation of the NO/soluble guanylyl cyclase/cGMP cascade, 1, 3 but whether this pathway is involved in the AT 2 R natriuretic response is unknown. In the present study, we examined renal functional responses, RI fluid (RIF), and tissue Ang II and Ang III levels to direct RI Ang III infusion to determine whether Ang III induces natriuresis by acting at AT 2 Rs in renal proximal tubule cells by a soluble guanylyl cyclase-dependent mechanism. We also determined the natriuretic effects of the following: (1) RI Ang III infusion in the presence or absence of the specific AT 2 R antagonist PD-123319 (PD); (2) RI Ang(1-7) infusion in the presence or absence of ACE inhibition with enalaprilate (to inhibit Ang [1] [2] [3] [4] [5] [6] [7] metabolism); and (3) RI Ang II infusion in the presence of the APA inhibitor EC-33 used to block Ang II degradation and shunt the octapeptide to Ang(1-7) in rats with concurrent systemic AT 1 R blockade. In addition, we studied the RI coinfusion of Ang III and APN inhibitor PC-18 in both the presence and absence of systemic AT 1 R blockade to determine the influence of AT 1 Rs on Ang III-induced natriuresis. In addition, we explored RI infusion of PC-18 alone in the presence of systemic AT 1 R blockade to determine whether endogenous Ang III can induce natriuresis. The results of these studies demonstrate that endogenous intrarenal Ang III but not Ang II or Ang(1-7) induces natriuresis via activation of AT 2 Rs in a soluble guanylyl cyclase-dependent manner, likely in the renal proximal tubule.
Methods

Animal Preparation
The experiments were conducted on 12-week-old female SpragueDawley rats except that the experiments in protocol 8 were conducted on 10-week-old male Sprague-Dawley rats. Please see the online-only Data Supplement for the following methods: renal cortical interstitial infusion, RIF microdialysis, mean arterial pressure (MAP) measurements, pharmacological agents, measurement of glomerular filtration rate (GFR) and fractional excretion of sodium (FE Na ) and lithium (FE Li ), measurement of Ang peptide levels in RIF and tissue, and AT 2 R Western blot analysis. Except where described otherwise, all of the protocols were performed on rats subjected to 24-hour systemic AT 1 R blockade with candesartan (CAND).
Protocols
Effects of Unilateral RI Infusion of Ang III on U Na V, MAP, GFR, FE Na , and FE Li in the Presence of Systemic AT 1 
R Blockade
The left (experimental) kidney received RI infusion of Ang III (3.5, 7, 14, and 28 nmol/kg per minute; each dose for 30 minutes) after a 30-minute control period with RI vehicle (V; 5% dextrose in water) infusion. The right (control) kidney received RI V infusion for all of the periods. U Na V, MAP, GFR, FE Na , and FE Li were quantified separately for the experimental and control kidneys for each infusion period.
Effects of Unilateral RI Infusion of Ang III؎AT 2 R Antagonist PD on U Na V and MAP in the Presence of Systemic AT 1 
The left (experimental) kidney received RI infusion of Ang III (3.5, 7.0,14.0, and 28.0 nmol/kg per minute; each dose for 30 minutes)ϮPD (10 g/kg per minute) throughout the 4 experimental periods after a 30-minute control period with RI V infusion. The right (control) kidney received RI V infusion for all of the periods. U Na V and MAP were quantified separately for the experimental and control kidneys for each infusion period. 
Effects of Unilateral
Effects of Systemic AT 2 R Agonist Compound 21 Alone and Combined With RI PD Infusion on U Na V and MAP in Uninephrectomized Male Sprague-Dawley Rats
Male rats (nϭ11) anesthetized with Inactin underwent acute unilateral nephrectomy. After a 1-hour control period, the rats received a systemic infusion of compound 21 at 100, 200, and 300 ng/kg per minute, each dose for 30 minutes either in the presence or absence of RI infusion of PD (10 g/kg per minute) or systemic AT 1 R blockade before the study. U Na V and MAP were quantified for the control and final infusion periods.
Effects of Systemic AT 1 R Blockade and Unilateral RI Infusion of Ang II or Ang III or Ang III؉PC-18 on Renal Tissue and RIF Levels of Ang II and Ang III
The left (experimental) kidney received RI infusion of Ang II (3.5, 7.0, 14.0, and 28.0 nmol/kg per minute; each dose for 30 minutes), Ang III, or Ang IIIϩPC-18 (25 g/min) after a 30-minute control period with RI V infusion. Renal tissue and RIF Ang II and III levels were separated using high-performance liquid chromatography and quantified separately by radioimmunoassay, as described previously.
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Statistical Analysis
Data are presented as meanϮ1 SE. Statistical significance was determined by using 1-way ANOVA followed by multiple comparisons testing with the Student-Newman-Keuls test with 95% confidence. The level of significance was set at PϽ0.05.
Results
R Blockade
As shown in Figure 1A , cumulative RI delivery of Ang III in the presence of systemic AT 1 R blockade with CAND induced statistically significant natriuresis at all of the infusion rates (Fϭ34.0; PϽ0.0001). U Na V increased from a control of 0.07Ϯ0.01 mol/min to 0.11Ϯ0.01 (PϽ0.01), 0.17Ϯ0.02 (PϽ0.01), 0.18Ϯ0.01 (PϽ0.001), and 0.13Ϯ0.02 mol/min (PϽ0.05) at 3.5, 7.0, 14.0, and 28.0 nmol/kg per minute of Ang III, respectively. RI Ang III infusion had no significant effect on MAP ( Figure 1B) , as monitored by a direct carotid artery cannula, or GFR ( Figure 1C ), as measured by inulin clearance. The rise in U Na V was accompanied by a significant increase in both FE Na (Fϭ14.6; PϽ0.0001) and FE Li (Fϭ14.9; PϽ0.0001). FE Na ( Figure 1D ) increased from a control of 0.26Ϯ0.04% to 0.57Ϯ0.06% (Pϭ0.01), 0.87Ϯ0.26% (PϽ0.0001), and 0.70Ϯ0.10% (Pϭ0.0003) at Ang III infusion rates of 7, 14, and 28 nmol/kg per minute, respectively. FE Li ( Figure 1E ) increased in a dose-dependent fashion from a control of 24.4Ϯ2.7% to 36.9Ϯ1.9% (Pϭ0.007), 47.4Ϯ4.0% (Pϭ0.0002), and 53.3Ϯ4.6% (PϽ0.001) at 7, 14, and 28 nmol/kg per minute of Ang III, respectively. There were no changes in U Na V, MAP, GFR, FE Na , or FE Li in the V-infused control kidneys. Because most of the experiments used systemically blocked AT 1 Rs for 24 hours, we measured total whole-cell AT 2 R protein expression in cortical kidney samples by Western blot analysis and demonstrated that there was no change in AT 2 R expression under these conditions (data not shown).
As depicted in Figure S1A (online-only Data Supplement), cumulative RI administration of Ang III in the presence of systemic CAND induced a rise in U Na V (Fϭ23.5; PϽ0.001). U Na V increased from a control value of 0.05Ϯ0.01 mol/min to a peak of 0.14Ϯ0.01 mol/min (PϽ0.0001) at an Ang III infusion rate of 14 nmol/kg per minute. The increase in U Na V in response to Ang III was abolished by coinfusion of the heptapeptide with AT 2 R antagonist PD. There was no significant change in MAP ( Figure S1B ) in any of these experiments or in U Na V in the V-infused control kidneys ( Figure S1A ).
Effects of Unilateral RI Infusion of Ang (1-7)؎ACE
Inhibitor Enalaprilate or Ang(1-7) Antagonist A779 on U Na V and MAP in the Presence of Systemic AT 1 
R Blockade
In contrast to the aforementioned results with Ang III, RI infusion of equimolar doses of Ang(1-7) ( Figure S1A ) did not increase U Na V at any of the administered infusion rates. Similarly, RI coinfusion of Ang(1-7) and ACE inhibitor enalaprilate (to reduce the catabolism of infused Ang [1] [2] [3] [4] [5] [6] [7] ) failed to increase U Na V. There was also no significant change in MAP ( Figure S1B ) in any of these experiments or in U Na V in the V-infused control kidneys ( Figure S1A ). We also demonstrated that Ang(1-7) does not engender natriuresis even in the absence of AT 1 R blockade with CAND and that Ang(1-7) antagonist A-779 alone has no effect U Na V (data not shown). In contrast to Ang III, RI infusion of Ang II ( Figure S1A ) failed to increase U Na V. To determine whether an increase in endogenous Ang(1-7) is capable of increasing U Na V, we administered APA inhibitor EC-33 interstitially to shunt endogenous Ang II to Ang(1-7). However, this maneuver also failed to increase U Na V ( Figure S1A) . Similarly, there were no significant changes in MAP ( Figure S1B ) in any of these experiments or in U Na V in the V-infused control kidneys ( Figure S1A ). After demonstrating that RI Ang III infusion induces significant natriuresis in the presence of systemically blocked AT 1 Rs, we designed a set of experiments to determine whether Ang IIIinduced natriuresis depends on reduced AT 1 R activation. As shown in Figure 2A , in the absence of systemic CAND infusion, Ang III alone failed to engender a natriuretic response. However, coinfusion with the APN inhibitor PC-18 enabled Ang III to induce a significant natriuresis (Fϭ23.7; PϽ0.0001). Coinfusion of Ang IIIϩPC-18ϩPD abolished the natriuresis induced by Ang III at 3.5, 7.0, and 14.0 nmol/kg per minute in the presence of APN inhibitor PC-18. During these experiments, no significant changes in MAP ( Figure 2B ) or U Na V (Figure 2A ) in the V-infused control kidneys were observed. Because PD decreased U Na V to a value below V-infused control kidneys in these experiments, we also provide a control that PD alone does not reduce U Na V (data not shown). Figure 3A , Ang IIIϩPC-18 induced a robust, dose-dependent natriuresis in the presence of CAND (Fϭ30.0; PϽ0.0001). U Na V increased from control values of 0.08Ϯ0.02 mol/min in a stepwise fashion to a peak of 0.32Ϯ0.08 mol/min (PϽ0.0001) at the highest infusion rate of Ang III (28 nmol/kg per minute). In the absence of systemic CAND, RI infusion of Ang IIIϩPC-18 induced a comparable natriuresis to that with CAND at 3.5 and 7.0 nmol/kg per minute (PϽ0.05 from control values; P value not significant from CAND). However, in the rats with uninhibited AT 1 Rs, Ang IIIϩPC-18 was unable to sustain the natriuresis at the higher Ang III infusion rates and for the duration of the study. The overall natriuretic response to Ang IIIϩPC-18 was greater in the presence than in the absence of systemic AT 1 R blockade (Fϭ6.7; PϽ0.0001). As shown in Figure 3B , MAP was significantly lower in the CAND-treated rats than in those without CAND (Fϭ28.4; PϽ0.0001), but MAP remained unaltered during the RI Ang IIIϩPC-18 infusions (P value not significant).
Effects of Unilateral
Effects of Unilateral RI Infusion of APN Inhibitor PC-18؎PD on U Na V and MAP in the Presence of Systemic AT 1 R Blockade
To determine whether endogenous Ang III is capable of inducing natriuresis, we infused PC-18 alone interstitially in AT 1 Rblocked rats. As shown in Figure 4A , PC-18 induced a sustained natriuresis (Fϭ14.7; PϽ0.0001) with U Na V rising from 0.05Ϯ0.004 mol/min to a peak of 0.09Ϯ0.008 mol/ min (PϽ0.05) after 60 minutes of infusion. The natriuretic response to RI PC-18 infusion was abolished by the coadministration of AT 2 R antagonist PD. During these experiments, no significant change in MAP ( Figure 4B ) or U Na V ( Figure 4A ) in the V-infused control kidneys was observed.
Effects of Unilateral RI Infusion of Ang III and
Ang III؉PC-18؎PD or ؎ODQ on RIF cGMP, U Na V, and MAP in the Presence of Systemic AT 1 
R Blockade
As shown in Figure 5A , RI administration of Ang III increased RIF cGMP concentrations (Fϭ8.49; PϽ0.0001). PC-18 did not significantly augment the cGMP response to Ang III. The increased cGMP response to Ang IIIϩPC-18 was abolished with both PD and ODQ. Ang III alone and in the presence of PC-18 increased natriuresis ( Figure 5B ; Fϭ6.5, PϽ0.0001; Fϭ12.55, PϽ0.0001, respectively). Natriuretic responses to Ang IIIϩPC-18 were numerically greater than with Ang III alone, although this did not achieve statistical significance (Fϭ1.90; Pϭ0.11). Ang III-induced natriuresis was abolished by both the AT 2 R blocker PD and by the guanlylyl cyclase inhibitor ODQ. There was no significant difference in MAP in response to any of the interstitially infused agents ( Figure 5C ).
Effects of Systemic AT 2 R Agonist Compound 21 Alone With or Without Systemic AT 1 R Blockade and Combined With RI Infusion of PD on U Na V and MAP in Uninephrectomized Male Rats
Compound 21 increased U Na V from 0.46Ϯ0.08 to 6.22Ϯ1.33 mol/min (PϽ0.01). This response was augmented by systemic AT 1 R blockade (PϽ0.05) and blocked by intrarenal PD (PϽ0.05; Figure S2 ). MAP did not change significantly after compound 21 or PD (data not shown). 
Measurement of RIF and Renal Tissue Ang II and III Levels in Response to Systemic AT 1 R Blockade and RI Infusion of Ang II or Ang III Alone and ؉PC-18
As demonstrated in Figure 6 , RIF Ang II ( Figure 6A ) and Ang III ( Figure 6B ) levels in the basal state were 76Ϯ12.0 and 77.4Ϯ12.1 fmol/mL, respectively (ratio, 1.0; Figure 6C ). Systemic AT 1 R blockade with CAND did not significantly change RIF Ang II or Ang III levels. RI Ang II infusion in the presence of systemic CAND increased RI Ang II levels by 8-fold (PϽ0.001) compared with those during CAND alone. Although numerically increased, Ang III levels were not significantly different from those with systemic CAND alone. As expected, RI administration of Ang III, although not increasing RIF Ang II levels, increased Ang III levels from those with CAND alone (PϽ0.01). RI coadministration of Ang IIIϩPC-18 further increased RIF Ang III levels to 789.7Ϯ115.9 fmol/mL (PϽ0.01) but unexpectedly increased Ang II levels significantly.
Baseline renal tissue levels of Ang II and Ang III (Figure S3A and S3B) were 313.0Ϯ60.9 and 77.8Ϯ18.1 fmol/g of kidney weight, respectively. Systemic AT 1 R blockade did not alter the levels of either peptide but significantly increased the ratio of Ang III:Ang II ( Figure S3C ). Ang II infusion increased both Ang II (PϽ0.01) and Ang III (PϽ0.05) and decreased the Ang III:II ratio (PϽ0.05). Ang III infusion increased levels of Ang III (PϽ0.0001) and also unexpectedly Ang II (PϽ0.01) but increased the ratio of Ang III:II. Ang III infusion in the presence of PC-18 also unexpectedly increased the levels of both peptides (each PϽ0.01) to approximately the same extent. Because Ang III increased the tissue concentrations of both peptides, we performed additional experiments in vitro in which Ang III was added to the assay system and Ang II was quantified. There was no significant cross-reactivity of Ang II with Ang III that could account for the increased renal Ang II in response to Ang III or Ang IIIϩPC-18 administration (data not shown).
Discussion
The present study demonstrates the ability of Ang III to induce natriuresis via activation of soluble guanylyl cyclase by AT 2 Rs specifically localized in the renal proximal tubule cell. RI Ang III-induced natriuresis was abolished by coinfusion with the highly selective AT 2 R antagonist PD, specific for AT 2 Rs in the low doses used in this study. 13 In the absence of changes in GFR, FE Na increased during Ang III infusions, indicating that the observed natriuretic effects of Ang III are attributable to reduced tubular transport and not to systemic or intrarenal hemodynamic changes. In Na ϩ -replete experimental animals, FE Li localizes changes in renal Na ϩ reabsorption to the proximal tubule with a maximum error rate of 4%.
14 FE Li increased in a dose-dependent fashion, strongly suggesting (but not unequivocally proving) that Ang III acts predominantly in the proximal tubule, where AT 2 Rs are highly expressed.
10,11 Ang III-induced natriuresis was accompanied by increased RIF cGMP levels and was abolished by the soluble guanylyl cyclase inhibitor ODQ, strongly suggesting that Ang III-induced natriuresis is mediated by renal production of cGMP.
Our study also provides data showing that, at equimolar concentrations, neither intrarenal Ang II nor Ang(1-7) engenders natriuresis in the AT 1 R blocked rat. We also demonstrated no effect of the Ang(1-7) antagonist A-779, excluding an effect of endogenous Ang(1-7) on Na ϩ excretion. Previous studies from our laboratory demonstrated that Ang II was only capable of inducing natriuresis in the presence of an APN inhibitor to decrease Ang III metabolism. 7, 9 In the present study, Ang II, at an equivalent molar infusion rate as Ang III, either in the presence or absence of APA inhibitor to retard Ang II degradation, was ineffective in increasing U Na V. In these studies, Ang(1-7) also, at the equivalent molar concentration, failed to induce natriuresis either when infused alone or in the presence of an ACE inhibitor to reduce its degradation. It is certainly possible that alternative pathways, such as neprilysin, 15 can metabolize Ang(1-7), but ACE has been identified as a major degrading enzyme for this peptide. 15, 16 Also, APA inhibition, which would be expected to increase Ang II, which would then be available for conversion to Ang(1-7) via ACE-2 and/or alternative pathways, did not induce natriuresis. Taken together, these results support the concept that Ang III is the predominant agonist of AT 2 R-mediated natriuresis.
Previous studies from our laboratory have indicated that Ang III-induced natriuresis requires the concurrent blockade of systemic AT 1 Rs. 7 Results from the present study confirm this finding. However, in the present study we demonstrated that, when APN is inhibited to reduce Ang III metabolism, the heptapeptide is capable of inducing natriuresis in the presence of unblocked systemic AT 1 Rs. Thus, in a pure physiological sense, intrarenal Ang III would not be expected to play a significant role in the control of Na ϩ excretion when AT 1 Rs are intact, because the antinatriuretic actions of Ang II via AT 1 Rs, which are widely expressed in the kidney, would overwhelm the ability of AT 2 Rs to engender natriuresis. AT 2 R-induced natriuresis would only apply when AT 1 Rs are blocked or, as shown by our data, when APN is blocked in the absence of AT 1 R inhibition. We also demonstrated that the aforementioned natriuretic response is specifically related to renal AT 2 R activation. In this regard, it is interesting to compare the natriuretic responses to Ang III with and without systemic AT 1 R blockade. In rats with AT 1 R blockade, natriuretic responses to Ang III and the APN inhibitor were sustained in a dose-dependent manner, whereas in those without AT 1 R blockade, an initial natriuretic response was followed by return to baseline levels in spite of increasing peptide infusion rates. These data suggest that AT 1 R blockade enhances both the magnitude and duration of the natriuretic response to Ang III, albeit in the short-term.
In light of these results, we hypothesized that endogenous Ang III is capable of inducing natriuresis in the normal rat. In AT 1 R-blocked rats, we found that intrarenal administration of the APN inhibitor PC-18 alone induced a significant and sustained natriuresis that was abolished by the AT 2 R antagonist PD. These results indicate that, in addition to exogenous Ang III, endogenous renal Ang III induces natriuresis via AT 2 R activation. The magnitude of the natriuretic response to PC-18 was relatively small compared with that attributed to exogenous Ang III in the presence of PC-18, indicating that renal heptapeptide biosynthesis may be a rate-limiting step in Ang III-induced natriuresis.
The present study is limited by the exclusive use of pharmacological agents as heuristic tools to dissect the relative contributions of Ang peptides to the natriuretic response. In the future, it will be important to use approaches targeting, for example, APN at the molecular level. However, our study does demonstrate that renal Ang II and III levels are approximately equal in the basal state, are appropriate for their respective peptide infusions, and that PC-18 effectively inhibits renal APN. The increase in renal Ang II during Ang III infusion may be because of product inhibition of APA, but this will require further study. 
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We used female rats for these studies. Hilliard et al 17, 18 have shown recently that AT 2 R activation caused a similar increase in Na ϩ excretion via an action at the renal tubule in both male and female Sprague-Dawley rats. Identified sex differences were limited to renal hemodynamic (vasodilatory) function that did not influence Na ϩ excretion in their studies. In addition, Hakam and Hussain 19 have shown that AT 2 R activation directly inhibits renal tubule sodium-potassium ATPase activity both in male obese Zucker rats and in male Sprague-Dawley rats. 20 Furthermore, Sabuhi et al 21 demonstrated that AT 2 R activation induces natriuresis via a renal tubule mechanism in male SpragueDawley rats. Thus, there is a large body of evidence in the literature that renal tubule AT 2 R activation induces natriuresis in both male and female rats. However, we do show here that compound 21, a highly selective AT 2 R agonist, 13 induces natriuresis in male rats and that this response is augmented by concomitant AT 1 R blockade and blocked with intrarenal PD.
In addition to the kidney, 2 other cardiovascular/hormonal systems have been linked to Ang III as a preferred agonist for AT 2 Rs, the coronary vascular bed and adrenal zona glomerulosa. In the coronary microcirculation, Ang III, rather than Ang II, is the preferred ligand to induce AT 2 R-mediated vasodilation. 22 Ang III is also the preferred agonist for AT 2 R-mediated aldosterone secretion from the adrenal cortex. 23 Together with the results of the present study, the evidence suggests that, at least in certain tissues, Ang III may be a better molecular fit within the AT 2 R binding pocket than Ang II. The precise molecular conformation that renders Ang III a better fit awaits future investigation.
Perspectives
In the present study in the normal Na ϩ -replete rat, we demonstrated that endogenous intrarenal Ang III increases U Na V and that this response is mediated by AT 2 Rs by a cGMP-dependent mechanism in the proximal tubule. We showed that Ang III is the predominant angiotensin peptide agonist at renal tubule AT 2 Rs, because neither Ang II nor Ang(1-7) altered U Na V in our experimental model. Our recent published studies have shown that spontaneously hypertensive rats have defective AT 2 Rmediated natriuresis, which can be restored by intrarenal APN inhibition. 24 On the basis of these findings, we hypothesize that, in hypertension, renal APN activity is increased, leading to accelerated Ang III metabolism reducing AT 2 R-mediated Na ϩ excretion. We further hypothesize that inhibition of APN activity could be beneficial in the treatment of hypertension. These hypotheses will require validation in future studies.
What Is Relevant?
• Endogenous intrarenal Ang III, but not Ang II or Ang(1-7), induces natriuresis by activation of AT2Rs in the renal proximal tubule.
• This action of AT2Rs is mediated by renal formation of cGMP.
• A major initiating event in hypertension is thought to be increased renal proximal tubule reabsorption of sodium.
• Renal AT1R activation increases proximal tubule sodium reabsorption, and this response is counteracted by renal AT2R activation triggered by endogenous intrarenal Ang III.
• Ang III activation of AT2Rs is markedly augmented by blocking APN.
• These studies suggest that APN inhibition would be a novel therapeutic target in hypertension.
Summary
This study demonstrates that endogenous intrarenal Ang III, but not Ang II or Ang(1-7), induces natriuresis via activation of AT 2 Rs in the proximal tubule via a cGMP-dependent mechanism and suggests APN inhibition as a potential therapeutic target in hypertension.
